Intensity Therapeutics INTS
NASDAQ INTS
$3.21 -0.07 (-2.13%)
As of: Oct 21, 2026 · 9:55 AM EDT

Intensity Therapeutics (INTS) Total Debt (2022)

Updated

Intensity Therapeutics (INTS) recorded Total Debt of $4.35 million in Q4 2022.

Analysis

Intensity Therapeutics (INTS) Total Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,128.06 Bn 1,096.64 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 615.47 Bn 534.00 Bn 17.26 Bn 49.04 Bn
3 AbbVie 504.80 Bn 477.91 Bn 12.70 Bn 70.82 Bn
4 Merck 368.45 Bn 322.83 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 298.44 Bn 262.43 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.92 Bn 235.60 Bn 12.86 Bn 32.35 Bn
7 Amgen 236.10 Bn 191.50 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 190.71 Bn 164.91 Bn 6.22 Bn 26.25 Bn
9 Pfizer 170.16 Bn 116.81 Bn 10.94 Bn 63.19 Bn
10 Intensity Therapeutics 8.69 Mn -30.07 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 4.35 Mn
API Access

Intensity Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=INTS&period=max&api_key=YOUR_API_KEY